ClinicalTrials.gg
RecruitingNCT07050173RHIGSHUpdated Jun 3, 2026

Monitoring Patients With Repetitive Head Impact With Gamma-glutamylcysteine Supplementation

A Phase 1 interventional study of Gamma-glutamylcysteine (GGC) in Repetitive Head Impacts, sponsored by Pravat Mandal. Recruiting at 1 site in United States. Open to participants aged 30 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Pravat Mandal · Phase 1, Interventional, and Prevention

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
30 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 312 studies in Brain Injuries with a site in United States — 57 open to participants now, 69 under way, none of them phase 3. Brain Injuries · United States.

Planned enrollment
132nd of 223
30 · median 42
Started
2026
with 13 others
Phase 1
16 of 312
6 open now
Primary completion
2027-11
later than 38 of 68 live
Registered
288th of 312
by date

Among the 312 studies in Brain Injuries with a site in United States, this one is the 132nd largest by planned enrollment of the 223 interventional ones that give a count, is one of 14 that started in 2026, is one of 16 in phase 1, reaches primary completion later than 38 of the 68 other live ones, and was the 288th registered.

Brain Injuries

947 studies on the registry are indexed under Brain Injuries; 236 are open to participants now.

Browse Brain Injuries studies →

Open to participants now

57 of the 312 studies in Brain Injuries with a site in United States are open now. Recruiting first, the newest first:

51 more — sign in →

All 57 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 153 Brain Injuries studies recruiting now, 76 (50%) set no upper age limit and 55 (36%) stop at 75 or younger; 39 take children under 18; 23 take healthy volunteers.

This study: 30 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 312 studies in Brain Injuries with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to test whether the gamma - glutamylcystiene (GGC) oral supplement can reach the brain and subsequently increase antioxidant glutathione (GSH) level in people with repetitive head impact (RHI). This will reduce the oxidative stress related injury in people with RHI.This unique study's main objective is to test the:

  1. Change in GSH in brain and blood levels through GGC supplementation.
  2. Change in the cognitive function in RHI patients due to GGC supplementation.
Read the detailed description

This study is designed to evaluate the effects of GGC supplementation in patients with a history of repetitive head impacts (RHI) who are at risk for developing Traumatic Encephalopathy Syndrome (TES). The trial will include specific individuals who satisfy the eligibility criteria.

03

Conditions studied

  • Repetitive Head Impacts

Browse trials for

Keywords

  • Brain injury
  • Glutathione
  • MR spectroscopy
  • Non- invasive
  • GGC
  • RHI
  • TES
  • Brain
  • Blood
04

Who can participate

Ages eligible
30 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Retired NFL player, retired Navy SEAL/army personnel with combat experience exposed to repetitive head impact;
  • Memory and behavioral complaint per self- or informant-report;
  • Age (30 to 70 years of age) years;
  • Able to read and write in English and to give consent to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments in the eyes, skin, or body.
  • Subjects with claustrophobia.
  • Subject with mild cognitive impairment [TICS score of 29 or lower OR >=1.0 standard deviations below age-expectation on at least two cognitive members within the same cognitive domain (e.g. memory, attention, etc.) on the baseline neuropsychological testing;
  • Subjects with a history of cancer;
  • Subjects with active psychosis or delirium;
  • Subjects with chronic kidney (creatinine > 1.5mg/dL) or liver disease ( ≥ 1.5 ; ALT ≥1.5 ULN) within 30 days prior to enrollment;
  • Subjects on antioxidant therapy (gingko biloba or N-acetylcysteine) or illicit drug abuse/dependence (cocaine, heroin, marijuana, or fentanyl;
  • Repeated head injury patients with neurosurgical intervention and;
  • Subjects with repeated head injury within the last 90 days.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Gamma - Glutamylcystiene

    Each participant will receive gamma-glutamyl cysteine (GGC) tablet orally 400mg (two times) per day once in the morning and once in the evening for 12 months.

    Drug: Gamma-glutamylcysteine (GGC)

Interventions

06

What researchers measure

Primary outcomes

  1. Changes in brain glutathione levels (mM) in people with Repetitive Head Injury (RHI) using Magnetic Resonance Spectroscopy in pre and post supplementation.

    (MRS) is a non-invasive imaging technique, to detect various neurochemical (e.g. glutathione) using MEGA-PRESS sequence from 1H MR spectroscopy.

    Time frame: 12 months

  2. Changes in baseline blood glutathione levels (µmol/l) in people with RHI due to GGC supplementation.

    Time frame: 12 months

  3. Changes in blood iron levels(ng/μl) in people with RHI due to GGC supplementation.

    Time frame: 12 months

Secondary outcomes

  1. Correlation between glutathione and iron levels in the brain and blood with dysbiotic features of the gut microbiome in people with RHI.

    Brain imaging, blood and stool samples will be collected to determine the correlation between glutathione and iron levels in the brain and blood with dysbiotic features of the gut microbiome in people with RHI.

    Time frame: 12 months

  2. Changes from baseline in the cognitive functions (immediate memory, visuospatial memory, language etc) using Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) in people with RHI .

    Interpretation: Higher scores \> 70 indicate greater cognitive function (PMID =36648917)

    Time frame: 12 months

  3. Changes in brain iron levels (ppb) in people with RHI using susceptibility mapping between pre and post supplementation.

    Time frame: 12 months

  4. Changes from baseline in the cognitive functions ( executive functions like attention, speed, and mental flexibility ) using Trail Making Test (TMT) A&B in people with RHI.

    Scoring Method: The average scores are as follows: * Trail A - 29 seconds * Trail B - 75 seconds Interpretation: Higher scores indicate greater impairment

    Time frame: 12 months

  5. Changes from baseline in the cognitive functions and emotional well-being using Delis-Kaplan Executive Functioning System (D-KEFS) Color Word Interference test in people with a RHI

    Interpretation: Higher score (\> 7) (PMID=21122190) indicates greater executive functions which includes cognitive abilities essential for tasks such as planning, problem-solving, and decision-making.

    Time frame: 12 months

  6. Changes from baseline in the cognitive functions and emotional well-being using Test of Premorbid Functioning (TOPF ) in people with RHI (PMID=36648917)

    Interpretation of the results: Higher scores (\>45 above 315191110 indicate better cognitive and memory function.

    Time frame: 12 months

  7. Changes from baseline in the cognitive functions and emotional wellbeing using Brief Symptom Inventory (BSI-18) (self-report) in people RHI .

    Scoring Method: Each item is scored on a 0-4 scale, with the total score indicating the severity of distress. Interpretation: Higher total scores indicate greater severity of psychological distress.

    Time frame: 12 months

  8. Changes from baseline in the cognitive functions and emotional well-being using PROMIS Cognitive Function -Short Form 8a (self-report) tool in people RHI.

    Scoring Method: Raw Score: 8-40 Interpretation: Lower scores on this measure indicate greater subjective cognitive difficulty.

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Mandal PK, Dwivedi D, Joon S, Goel A, Ahasan Z, Maroon JC, Singh P, Saxena R, Roy RG. Quantitation of Brain and Blood Glutathione and Iron in Healthy Age Groups Using Biophysical and In Vivo MR Spectroscopy: Potential Clinical Application. ACS Chem Neurosci. 2023 Jun 21;14(12):2375-2384. doi: 10.1021/acschemneuro.3c00168. Epub 2023 May 31. PubMed 37257017 ↗
  • Mandal PK, Saharan S, Tripathi M, Murari G. Brain glutathione levels--a novel biomarker for mild cognitive impairment and Alzheimer's disease. Biol Psychiatry. 2015 Nov 15;78(10):702-10. doi: 10.1016/j.biopsych.2015.04.005. Epub 2015 Apr 14. PubMed 26003861 ↗

Individual participant data

Plan to share: Yes — Clinical study report data will be provided after the study data is analyzed and published. A comprehensive report will be sent to the IRB. The respective agency will be reported accordingly. Requests for the release of data must be submitted in writing to the PI, clearly stating the purpose of the request, the specific data needed, and the intended use. The PI, in collaboration with the research team, will review each request to ensure compliance with institutional policies, ethical standards, and any relevant data use agreements.

Supporting information: Clinical study report

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for Nov 2027, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2025
First posted
Jul 3, 2025
StartActual
May 1, 2026
Primary completionEst.
Nov 1, 2027
CompletionEst.
Dec 27, 2027
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07050173
Lead sponsor
Pravat Mandal
Collaborators
Chuck Noll Foundation
Responsible party
Pravat Mandal (Research Assistant Professor, University of Pittsburgh) — Sponsor-investigator
First posted
Jul 3, 2025
Start date
May 1, 2026
Primary completion
Nov 1, 2027 (estimated)
Completion
Dec 27, 2027 (estimated)
Last update
Jun 3, 2026

Study contacts

Pravat K MANDAL, PHD
Contact
mandalpk@pitt.edu
4126999561
Pravat K Mandal, PhD
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gamma-glutamylcysteine

Start the discussion